GILD Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
Gilead Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$75.27 |
52 Week High | US$89.74 |
52 Week Low | US$61.45 |
Beta | 0.39 |
1 Month Change | -2.30% |
3 Month Change | -2.84% |
1 Year Change | 19.74% |
3 Year Change | 20.92% |
5 Year Change | -2.51% |
Change since IPO | 11,794.53% |
Recent News & Updates
Recent updates
We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt
Aug 11Here's Why Gilead Sciences (NASDAQ:GILD) Has Caught The Eye Of Investors
Jul 04Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year
Jun 13Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75
May 30Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.75
May 16Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's
May 02Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet
Apr 17Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's
Feb 21Gilead Sciences (NASDAQ:GILD) Will Pay A Larger Dividend Than Last Year At $0.75
Feb 07Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 41% Discount?
Dec 05These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well
Nov 16Gilead's Kite gains license to Refuge Biotechnologies platform for blood cancer treatments
Oct 20Gilead's Quality And Growth Potential Are Underappreciated
Oct 14Gilead Sciences: Becoming A Cure
Oct 03A Dive Into Gilead Sciences' New HIV Medication
Sep 22Gilead Sciences goes ex-dividend tomorrow
Sep 13Gilead Sciences: Don't Miss The Transformation
Sep 01Gilead Is Too Cheap To Ignore And Set To Soar
Aug 21Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite Sensibly
Aug 18Shareholder Returns
GILD | US Biotechs | US Market | |
---|---|---|---|
7D | -0.5% | -0.5% | -1.5% |
1Y | 19.7% | 10.8% | 13.8% |
Return vs Industry: GILD exceeded the US Biotechs industry which returned 10.8% over the past year.
Return vs Market: GILD exceeded the US Market which returned 13.8% over the past year.
Price Volatility
GILD volatility | |
---|---|
GILD Average Weekly Movement | 2.8% |
Biotechs Industry Average Movement | 9.0% |
Market Average Movement | 5.6% |
10% most volatile stocks in US Market | 14.3% |
10% least volatile stocks in US Market | 2.5% |
Stable Share Price: GILD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: GILD's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 17,000 | Dan O'Day | https://www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
GILD fundamental statistics | |
---|---|
Market Cap | US$93.79b |
Earnings (TTM) | US$5.48b |
Revenue (TTM) | US$27.38b |
17.1x
P/E Ratio3.4x
P/S RatioIs GILD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GILD income statement (TTM) | |
---|---|
Revenue | US$27.38b |
Cost of Revenue | US$5.63b |
Gross Profit | US$21.75b |
Other Expenses | US$16.26b |
Earnings | US$5.48b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 4.40 |
Gross Margin | 79.42% |
Net Profit Margin | 20.03% |
Debt/Equity Ratio | 119.7% |
How did GILD perform over the long term?
See historical performance and comparison